Literature DB >> 14733303

Long 3 x 8 hr dialysis: a three-decade summary.

Bernard Charra1, Charles Chazot, Guillaume Jean, Jean-Marc Hurot, Thierry Vanel, Jean-Claude Terrat, Cyril VoVan.   

Abstract

A long hemodialysis (HD), 3 x 8 hours/week, has been used without significant modification in Tassin for 35 years with excellent morbidity and mortality results. It can be performed during the day or overnight. The relatively good survival is mainly due to a lower cardiovascular mortality than usually reported in dialysis patients. This in turn is mainly due to the good control of blood pressure (BP) including drug-free hypertension control and low incidence of intradialytic hypotension. This control of BP is probably the result of the tight extracellular volume normalization (dry weight), although one cannot exclude the effect of other factors such as serum phosphorus control well achieved using long dialysis. The high dose of small and even more of middle molecules is another essential virtue of long dialysis, leading to good nutrition, correction of anemia, control of serum phosphate and potassium with low doses of medications and providing a very cost-effective treatment. In 2002 one must aim at optimal rather than just adequate dialysis. Optimal dialysis needs to correct as perfectly as possible each and every abnormality due to renal failure. It can be achieved using longer (or more frequent) sessions. Overnight dialysis is the most logical way of implementing long HD with the lowest possible hindrance on patient's life. Due to the change in case mix a decreasing number of patients are able or willing to go on overnight dialysis, education to be autonomous is more difficult, but the benefit is still there.

Entities:  

Mesh:

Year:  2003        PMID: 14733303

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  12 in total

1.  Acquired cystic kidney disease and arterial hypertension in hemodialysis patients.

Authors:  Robert Ekart; Radovan Hojs
Journal:  Wien Klin Wochenschr       Date:  2006       Impact factor: 1.704

Review 2.  Body Fluids in End-Stage Renal Disease: Statics and Dynamics.

Authors:  Jeroen P Kooman; Frank M van der Sande
Journal:  Blood Purif       Date:  2018-12-05       Impact factor: 2.614

Review 3.  Home haemodialysis and uraemic toxin removal: does a happy marriage exist?

Authors:  Raymond Vanholder; Sunny Eloot; Nathalie Neirynck; Wim Van Biesen
Journal:  Nat Rev Nephrol       Date:  2012-08-28       Impact factor: 28.314

4.  Drug Selection for Treating Hypertension in Dialysis Patients: More to Consider than BP-Lowering Potency.

Authors:  Tariq Shafi; Dana C Miskulin
Journal:  Clin J Am Soc Nephrol       Date:  2020-07-16       Impact factor: 8.237

5.  Renal Association Clinical Practice Guideline on Haemodialysis.

Authors:  Damien Ashby; Natalie Borman; James Burton; Richard Corbett; Andrew Davenport; Ken Farrington; Katey Flowers; James Fotheringham; R N Andrea Fox; Gail Franklin; Claire Gardiner; R N Martin Gerrish; Sharlene Greenwood; Daljit Hothi; Abdul Khares; Pelagia Koufaki; Jeremy Levy; Elizabeth Lindley; Jamie Macdonald; Bruno Mafrici; Andrew Mooney; James Tattersall; Kay Tyerman; Enric Villar; Martin Wilkie
Journal:  BMC Nephrol       Date:  2019-10-17       Impact factor: 2.388

Review 6.  Systolic blood pressure and mortality in patients on hemodialysis.

Authors:  Tara I Chang
Journal:  Curr Hypertens Rep       Date:  2011-10       Impact factor: 5.369

7.  Outcomes associated with in-center nocturnal hemodialysis from a large multicenter program.

Authors:  Eduardo Lacson; Weiling Wang; Keith Lester; Norma Ofsthun; J Michael Lazarus; Raymond M Hakim
Journal:  Clin J Am Soc Nephrol       Date:  2009-12-03       Impact factor: 8.237

8.  Ten years experience of in-center thrice weekly long overnight hemodialysis.

Authors:  Joanna Ruth Powell; Oyeniran Oluwaseun; Yook Mun Woo; Neal Padmanabhan; Eliyanachii Narasinghan; Carol Latta; Julie Tortolano; Alan G Jardine; Colin C Geddes
Journal:  Clin J Am Soc Nephrol       Date:  2009-05-21       Impact factor: 8.237

Review 9.  Genomic damage in endstage renal disease-contribution of uremic toxins.

Authors:  Nicole Schupp; August Heidland; Helga Stopper
Journal:  Toxins (Basel)       Date:  2010-10-11       Impact factor: 4.546

10.  International practice patterns and factors associated with non-conventional hemodialysis utilization.

Authors:  Nathan Allen; Daniel Schwartz; Paul Komenda; Robert P Pauly; Deborah Zimmerman; Gemini Tanna; Jeffery Schiff; Claudio Rigatto; Manish M Sood
Journal:  BMC Nephrol       Date:  2011-12-05       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.